Brachial artery flow-mediated vasodilation is correlated with coronary vasomotor and fibrinolytic responses induced by bradykinin

Hypertension Research

Volumn 28, Issue 1, 2005, Pages 59-66

  Tarutani, Yasuhiro ^a   Matsumoto, Tetsuya ^a   Takashima, Hiroyuki ^a   Yamane, Tetsunobu ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Bradykinin; Coronary; Endothelial function; Fibrinolytic activity

Indexed keywords

BRADYKININ; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIGEN DETECTION; ARTERY DIAMETER; ARTICLE; BRACHIAL ANGIOGRAPHY; BRACHIAL ARTERY; COLOR ULTRASOUND FLOWMETRY; COMPARATIVE STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORRELATION FUNCTION; DOSE RESPONSE; ECHOGRAPHY; FEMALE; FIBRINOLYSIS; HEART PROTECTION; HEMATOCRIT; HUMAN; HYPEREMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; THROMBOSIS; VASCULAR ENDOTHELIUM; VASODILATATION; VASOMOTOR REFLEX;

ADULT; AGED; BRACHIAL ARTERY; BRADYKININ; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYSIS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; TISSUE PLASMINOGEN ACTIVATOR; VASODILATION;

EID: 17844380295     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.28.59     Document Type: Article

References (31)

1. Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
2. Halcox JP, Schenke WH, Zalos G, et al: Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-658.
3. Fathi R, Haluska B, Isbel N, Short L, Marwick TH: The relative importance of vascular structure and function in predicting cardiovascular events. J Am Coll Cardiol 2004; 43: 616-623.
4. Ridker PM, Hebert PR, Fuster V, Hennekens CH: Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet 1993; 341: 1165-1168.
5. Jansson JH, Olofsson BO, Nilsson TK: Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030-2034.
6. Thogersen AM, Jansson JH, Boman K, et al: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-2247.
7. Tomiyama H, Kushiro T, Okazaki R, Yoshida H, Doba N, Yamashina A: Influences of increased oxidative stress on endothelial function, platelets function, and fibrinolysis in hypertension associated with glucose intolerance. Hypertens Res 2003; 26: 295-300.
8. Laurent S, Lacolley P, Brunel P, Laloux B, Pannier B, Safar M: Flow-dependent vasodilation of brachial artery in essential hypertension. Am J Physiol 1990; 258: H1004-H1011.
9. Celermajer DS, Sorensen KE, Gooch VM, et al: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
10. Sorensen KE, Celermajer DS, Spiegelhalter DJ, et al: Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995; 74: 247-253.
11. Anderson TJ, Uehata A, Gerhard MD, et al: Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-1241.
12. Playford DA, Watts GF: Non-invasive measurement of endothelial function. Clin Exp Pharmacol Physiol 1998; 25: 640-643.
13. Takase B, Uehata A, Akima T, et al: Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 1998; 82: 1535-1599.
14. Linz W, Wiemer G, Scholkens BA: Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Am J Cardiol 1997; 80: 118A-123A.
15. Minai K, Matsumoto T, Horie H, et al: Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2001; 37: 1565-1570.
16. Corretti MC, Anderson TJ, Benjamin EJ, et al: Guidelines for the ultrasound assessment of endothelial dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
17. Matsumoto T, Minai K, Horie H, et al: Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003; 41 1373-1379.
18. Ohira N, Matsumoto T, Tamaki S, et al: Angiotensin-converting enzyme insertion/deletion polymorphism modulates coronary release of tissue plasminogen activator in response to bradykinin. Hypertens Res 2004; 27: 39-45.
19. Doucette JW, Corl PD, Payne HM, et al: Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation 1992; 85: 1899-1911.
20. Matsuo S, Matsumoto T, Takashima H, et al: The relationship between flow-mediated brachial artery vasodilation and coronary vasomotor responses to bradykinin: comparison with those to acetylcholine. J Cardiovasc Pharmacol 2004; 44: 164-170.
21. Desta B, Vanhoutte PM, Boulanger CM: Inhibition of the angiotensin converting enzyme by perindoprilat and release of nitric oxide. Am J Hypertens 1995; 8: 1S-6S.
22. Groves P, Kurz S, Just H, et al: Role of endogenous bradykinin in human coronary vasomotor control. Circulation 1995; 92: 3424-3430.
23. Hornig B, Kohler C, Drexler H, Drexler H: Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115-1118.
24. Makimattila S, Liu ML, Vakkilainen J, et al: Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care 1999; 22: 973-981.
25. Zeiher AM, Drexler H, Wollschlager H, Just H: Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391-401.
26. Furumoto T, Saito N, Dong J, Mikami T, Fujii S, Kitabatake A: Association of cardiovascular risk factors and endothelial dysfunction in japanese hypertensive patients: implications for early atherosclerosis. Hypertens Res 2002; 25: 475-480.
27. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97: 2213-2221.
28. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ: Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
29. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-641.
30. Meigs JB, Mittleman MA, Nathan DM, et al: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283: 221-228.
31. Zeiher AM, Schachinger V, Minners J: Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995; 92: 1094-1100.